Scientists and longevity advocates are increasingly making an economic case for tackling the biology of aging, arguing that healthier, longer lives could reduce the enormous costs associated with chronic disease and declining workforce participation.

For years, the strongest argument for developing therapies that slow or reverse aging has been a simple one: reducing human suffering and preventing disease and death.

But a growing number of advocates are now making another argument, one aimed squarely at governments and policymakers: treating aging could deliver enormous economic benefits.

As populations around the world grow older, governments face rising healthcare costs, pension obligations and a shrinking share of people able to work. Advocates say therapies that could keep people healthier for longer may help address all three challenges.

The economic case for healthier aging

The scale of the problem is already enormous.

In the United States, chronic health conditions are estimated to cost about $1.1 trillion a year in direct costs, equivalent to roughly 5.8% of GDP. When lost productivity and other indirect costs are included, the estimated economic impact rises to about $3.7 trillion, or nearly 20% of U.S. GDP.

That has led to a growing question: What if some of these costs could be reduced by targeting aging itself, the underlying biological process that drives many chronic diseases?

Supporters of longevity research argue that improving health in middle and later life could allow more people to remain active, independent and economically productive for longer.

Speed could be just as important as longevity

There is another issue governments may need to consider: how quickly longevity technologies could advance.

A gradual increase in life expectancy over several decades would give pension systems, insurers, healthcare providers and economies plenty of time to adapt.

A much faster improvement could be very different.

Some researchers believe emerging “system-level” approaches to aging could eventually produce significant changes in healthspan and lifespan rather than the small, incremental gains seen historically. If such therapies become effective and widely available, existing economic and demographic forecasts could be disrupted.

That could force governments, insurers and pension systems to rethink assumptions that have been built around today’s life expectancy.

From medical research to economic strategy

Advocates therefore argue that longevity research should no longer be viewed solely as a healthcare issue.

They are calling for greater investment in basic aging research, clinical trials, translational research and public-private partnerships aimed at turning discoveries into treatments.

The argument is similar to the rationale behind major public investments in medical breakthroughs during the 20th century, including antibiotics and vaccines: government-supported research can produce benefits far beyond the laboratory.

But there is an important distinction.

The fundamental case for treating aging is not simply about protecting pension systems or increasing economic output. At its core, longevity research is about preventing disease, preserving health and reducing the years of suffering that accompany aging.

The economic benefits, advocates argue, could be a powerful additional reason for governments to take the science seriously.

If therapies that meaningfully extend healthy life become possible, the question may no longer be whether society can afford to invest in longevity research, but whether it can afford not to.